Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarNCT07213973 · readout in 584 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40estimated
Sites
30
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-02 | actual | When the study began enrolling |
| Primary completion | 2028-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa (HS)
Intervention
- Drug: Povorcitinib — also filed as INCB054707
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with Treatment-Emergent Adverse Events (TEAEs)
measured Baseline through Week 54
Apparent clearance
measured Up to Week 24
Apparent volume of distribution
measured Up to Week 24
Apparent oral absorption rate constant
measured Up to Week 24
Absorption lag time
measured Up to Week 24
Maximum plasma drug concentration at steady state
measured Up to Week 24
Average plasma drug concentration at steady state
measured Up to Week 24
Plasma concentration at steady state for the dosing interval
measured Up to Week 24
Time to maximum plasma concentration at steady state
measured Up to Week 24
Terminal half-life
measured Up to Week 24
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed